M184V/I Mutation May Have Little To No Impact On Virologic Suppression Among Patients With HIV Infection Who Switch To Dolutegravir Plus Lamivudine, Study Finds

Infectious Disease Advisor (12/6) reports, “An M184V/I mutation may have little to no impact on virologic suppression among patients with HIV infection who switch to dolutegravir plus lamivudine, according to study findings.” These findings were published in Open Forum Infectious Diseases.